Pediatrix Medical Group, Inc. (MD) Stock Price & How to Invest

Pediatrix Medical Group (NYSE: MD), founded in 1979 and known as MEDNAX until its 2022 rebrand, provides hospital-based physician staffing and clinical services concentrated in neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and related anesthesiology support. Its clinicians largely staff neonatal intensive care units and other hospital departments under contracts with hospital partners, with revenue driven by patient volumes, payer reimbursement, contract administrative fees and revenue-cycle collections.

The investment picture is one of a mature, low-multiple services business working through a deliberate simplification. Recent results show revenue and margins improving on the strength of pricing (roughly 4% in both Q1 and Q2 2026), better collections, higher administrative fees and increased neonatology acuity, even as patient volumes across service lines drift modestly lower. Management has been divesting non-core practices to sharpen focus on core women's and children's services, improve profitability and pay down debt, which shrinks the revenue base but is intended to lift quality of earnings. The stock trades at a meaningful discount to healthcare-sector peers, a gap that reflects both the restructuring drag and the cost pressures typical of physician-staffing models. In the June 2026 quarter net revenue rose about 4.1% to roughly $487.8 million and adjusted EPS of $0.63 beat the ~$0.59 consensus, while same-unit patient volumes fell about 2.1%. Trailing twelve-month revenue is about $1.95 billion with net income near $175 million, and the stock's 70% one-year rise has pushed it to the top of its 52-week range.

Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. Physician compensation, salaries and staffing costs can squeeze already tight margins if pricing gains slow. Patient volumes have been declining in parts of the business, including maternal-fetal medicine and neonatology, so growth leans heavily on pricing and payer mix rather than demand. The business is exposed to government and commercial reimbursement policy, hospital-contract renewals and concentration in a small set of subspecialties. Any reversal in payer mix or collections would hit results quickly given the thin operating margins. After a 70% one-year gain the shares trade above the mean analyst target with a consensus hold rating, and consensus for the September 2026 quarter calls for EPS of about $0.65, roughly 3% below a year earlier, so expectations leave less cushion than they did at the start of 2026. The balance sheet carries about $620 million of debt against roughly $404 million of cash.

6 analysts publish price targets on MD, averaging $26.33 against a $27.38 price as of October 2026, or -3.8%. The published targets run from $21.00 to $28.00, a narrow spread, and the ratings split 1 buy, 6 hold, 0 sell. Over the last six months there have been 4 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Pediatrix Medical Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Pricing and reimbursement strength. Pediatrix has been generating same-unit revenue growth through pricing gains of around 4% (repeated in the second quarter of 2026), supported by strong revenue-cycle cash collections, higher contract administrative fees from hospital partners and a slightly favorable payer mix. The most optimistic published target, $28.00, assumes this works close to its best case.

The case against. Portfolio restructuring and practice divestitures continue to pressure headline revenue and narrow revenue diversification in a sector with several large, well-capitalized competitors. The most pessimistic target, $21.00, is roughly what MD is worth if this bites instead.

Read the full bull and bear case on MD, including what would have to change to break either one. Walnut is not an investment adviser.

No. Pediatrix Medical Group, Inc. (MD) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Pediatrix Medical Group, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.95B, up ~4% year over year in Q2 2026
• Q2 2026 net revenue: ~$488M
• Net margin (TTM): ~9%, net income ~$175M
• EPS (TTM / forward): ~$2.09 / ~$2.44
• P/E (trailing / forward): ~13x / ~11x
• FY2026 adj. EBITDA guidance: ~$280M-$300M (reaffirmed with Q2)
• Market cap: ~$2.2B; no dividend

Pediatrix trades near 13x trailing earnings, still below the roughly 20x-plus average for healthcare-services peers, though the stock's roughly 29% gain in 2026 has narrowed the gap. Q2 2026 revenue rose about 4.1% year on year to roughly $488 million and adjusted EPS of $0.63 beat consensus, with full-year adjusted EBITDA guidance held near $290 million at the midpoint. Third-quarter results on November 2, 2026 carry a consensus near $0.65 EPS on about $498 million of revenue.

Other names that sit close to MD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Pediatrix is a turnaround-flavored, low-multiple physician-services business where pricing and cost discipline are offsetting soft volumes and a smaller footprint after divestitures.

Whether MD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MD a buy or a sell?, and where the stock could go from here in the MD stock forecast.

For income investors, whether MD pays a dividend and how the payout looks is covered in does MD pay a dividend? And to weigh MD against a peer, read the full side-by-side comparisons: MD vs THC and MD vs UHS.